Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors?

@article{Demir2013DoesIP,
  title={Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors?},
  author={Lutfiye Demir and Nese Ekinci and Cigdem Erten and Yuksel Kucukzeybek and Ahmet Alacacıoğlu and Isil Somali and Alper Can and Ahmet Dirican and Vedat Bayoğlu and Murat Akyol and Fulya Çakalağaoğlu and Mustafa Oktay Tarhan},
  journal={Asian Pacific journal of cancer prevention : APJCP},
  year={2013},
  volume={14 8},
  pages={
          4751-8
        }
}
BACKGROUND To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). MATERIALS AND METHODS Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. RESULTS Median overall survival (OS) of the whole study group was 74.9 months (42.8-107… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

VIEW 1 EXCERPT

Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib: Results from the BFR14 phase III trial of the French Sarcoma Group

  • F Bertucci, A Blesius, PA Cassier
  • ASCO Meeting Abstracts,
  • 2011
VIEW 1 EXCERPT

Prognostic relevance of genetic aberrations in gastrointestinal stromal tumors

  • NN Mazurenko
  • ASCO GI Cancery Symposium,
  • 2011